Business Context and Reporting Period
This Form 8-K filing by Minerva Neurosciences, Inc. reports corporate governance events occurring on December 10, 2017. The filing details the election of two new independent directors to the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to director compensation:
- Annual Cash Compensation: $35,000 per director.
- Stock Options: 40,000 shares per director granted under the 2013 Equity Incentive Plan.
- Exercise Price: $5.70 per share (based on the closing price on December 8, 2017).
- Vesting Schedule: Monthly vesting over three years, contingent on continued service.
Material Changes
The primary material change is the expansion of the Board of Directors with the addition of Hans Peter Hasler and William Doyle, both designated as Class I directors. No financial or operational changes are reported in this document.
Guidance, Outlook, and Risks
This filing contains no financial guidance, outlook, or management commentary regarding business performance. The document notes standard indemnification agreements were executed, requiring the Company to indemnify the new directors against certain liabilities and advance expenses related to their service. No unusual items or specific risks are disclosed beyond standard governance procedures.
Investor Verification Checklist
- Verify the independence status of the newly appointed directors, Hans Peter Hasler and William Doyle.
- Confirm the total number of outstanding shares and the dilution impact of the 80,000 new options granted.
- Review the Company's 2013 Equity Incentive Plan to understand remaining option availability.
- Check the press release (Exhibit 99.1) for additional context on the strategic rationale for these appointments.